Replies to post #64461 on Biotech Values

[DewDiligence]

The main difference DNA’s employees are likely to see from Roche’s full takeover (assuming it goes through) is that they will get Roche stock options instead of DNA options. If I were charged with negotiating this deal from DNA’s side, I would demand that Roche list its own shares on a US exchange.

[DewDiligence]

>The likes of Levinson, Desmond~Hellmann, Juelsgaard, Sheller and Yang, might take flight, retire from their huge DNA windfalls or accept their new roles with Roche.<

Levinson will probably retire in the next few years. I think Hellmann is in line to be top dog at DNA (and a member of Roche’s BoD) if she wants it.

[masterlongevity]

IMHO, knowing all of those indivuals 1st hand, they will all leave if the buyout is completed.

They feel that they have accomplished a life's work already and certainly don't need to work anymore,a nd sure as hell won't work for big pharma

Art will retire
Hellman will become a CEO
Ebersman will become a CEO
Yang and Scheller will become functional heads at smaller biotech because they love the research